Pharmaceuticals News and Research

RSS

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

RoundTable Healthcare Partners announces sale of Bioniche Pharma to Mylan for $550M

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Bioniche Pharma Holdings Limited to Mylan Inc., a leading, global generic and specialty pharmaceutical company, for $550 million in cash.

8 Sep 2010

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of - 20,000.

8 Sep 2010

La Jolla Pharmaceutical seeks clinical product for lupus treatment

La Jolla Pharmaceutical Company provided an update today that the Company is actively seeking and evaluating potential pharmaceutical products for in-licensing or acquisition and has engaged consultants to determine whether there is any potential for the further development of Riquent for the treatment of lupus.

8 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Israeli Supreme Court dismisses Taro's appeal in favor of Sun Pharma

Sun Pharmaceutical Industries Ltd. today announced that the Supreme Court of Israel has unanimously dismissed the appeal by Taro Pharmaceutical Industries Ltd. of the previous ruling by the Tel-Aviv District Court holding that the Israeli special tender offer (STO) rules do not apply to the Tender Offer by Sun's subsidiary, Alkaloida Chemical Company Exclusive Group Ltd., to purchase all outstanding Ordinary Shares of Taro for USD 7.75 net per Ordinary Share in cash.

8 Sep 2010

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx Pharmaceuticals, Inc. today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Abbott completes acquisition of Piramal's Healthcare Solutions

Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.

8 Sep 2010

Children's Hospital Boston engages Particle Sciences for drug product development services

Particle Sciences Inc. (PSI), a leading pharmaceutical Contract Research Organization (CRO), has been engaged by Children's Hospital Boston to help advance early stage molecules and drug innovations into new therapeutic products for patient care. Under the established framework between Children's and PSI, Particle Sciences provides drug product development services aimed at progressing the specific drug or drug product candidate to the point where it becomes attractive to potential licensees.

8 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Mylan completes acquisition of Bioniche Pharma

Mylan Inc. today announced it has completed the acquisition of Bioniche Pharma Holdings Limited sooner than anticipated.

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

DiaTech Oncology has announced the filing of a patent for Drug Discovery that will provide a new strategy and approach to validate drugs that may be more effective in treating cancer patients

8 Sep 2010

Alzheimer's disease drug market to increase from $4.3 billion to $13.3 billion in 2019: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Sep 2010

Watson Laboratories receives FDA approval for Zarah tablets

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Zarah (drospirenone and ethinyl estradiol tablets) 3 mg/0.03 mg, the generic equivalent to Bayer's Yasmin.

7 Sep 2010

UCSF scientists to receive two grants for personalized medicine research

UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual's response to medication and to strengthen a global network of researchers involved in these efforts.

7 Sep 2010

Quintiles new lab in Japan achieves CAP accreditation

Quintiles today announced that its new lab in Tokyo, Japan has received accreditation from the College of American Pathologists (CAP), joining the largest network of fully harmonized, CAP-accredited central labs in the world.

7 Sep 2010

Oragenics launches oral care probiotic products through GNC Stores

Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.

7 Sep 2010